SEC Form 4 · accession 0001140361-17-032509
IDEXX LABORATORIES INC /DE · IDXX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jonathan W Ayers
Officer — Chairman, President & CEO · Director
Period of report
Aug 14, 2017
Accepted (ET)
Aug 16, 2017 · 9:32 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000874716
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 14, 2017 | M | 18,000 | $38.795 | A | 1,043,034 | D | |
| Common StockF1 | Aug 14, 2017 | S | 18,000 | $154.9076 | D | 1,025,034 | D | |
| Common Stock | Aug 14, 2017 | M | 2,000 | $38.795 | A | 1,027,034 | D | |
| Common Stock | Aug 15, 2017 | M | 14,900 | $38.795 | A | 1,041,934 | D | |
| Common StockF2 | Aug 15, 2017 | S | 14,900 | $154.7146 | D | 1,027,034 | D | |
| Common Stock | Aug 15, 2017 | M | 5,100 | $38.795 | A | 1,032,134 | D | |
| Common StockF3 | Aug 15, 2017 | S | 5,100 | $154.3334 | D | 1,027,034 | D | |
| Common Stock | Aug 15, 2017 | M | 2,000 | $38.795 | A | 1,029,034 | D | |
| Common Stock | Aug 16, 2017 | M | 20,000 | $38.795 | A | 1,049,034 | D | |
| Common StockF4 | Aug 16, 2017 | S | 20,000 | $155.4744 | D | 1,029,034 | D | |
| Common Stock | Aug 16, 2017 | M | 2,000 | $38.795 | A | 1,031,034 | D | |
| Common Stock | holding | — | — | — | 98,000 | I | by Ayers Family Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right-to-buy)F6,F5 | $38.795 | Aug 14, 2017 | M | 18,000 | D | — | Feb 13, 2018 | Common Stock | 18,000 | 307,000 | D |
| Non-Qualified Stock Option (right-to-buy)F6,F5 | $38.795 | Aug 14, 2017 | M | 2,000 | D | — | Feb 13, 2018 | Common Stock | 2,000 | 305,000 | D |
| Non-Qualified Stock Option (right-to-buy)F6,F5 | $38.795 | Aug 15, 2017 | M | 14,900 | D | — | Feb 13, 2018 | Common Stock | 14,900 | 290,100 | D |
| Non-Qualified Stock Option (right-to-buy)F6,F5 | $38.795 | Aug 15, 2017 | M | 5,100 | D | — | Feb 13, 2018 | Common Stock | 5,100 | 285,000 | D |
| Non-Qualified Stock Option (right-to-buy)F6,F5 | $38.795 | Aug 15, 2017 | M | 2,000 | D | — | Feb 13, 2018 | Common Stock | 2,000 | 283,000 | D |
| Non-Qualified Stock Option (right-to-buy)F6,F5 | $38.795 | Aug 16, 2017 | M | 20,000 | D | — | Feb 13, 2018 | Common Stock | 20,000 | 263,000 | D |
| Non-Qualified Stock Option (right-to-buy)F6,F5 | $38.795 | Aug 16, 2017 | M | 2,000 | D | — | Feb 13, 2018 | Common Stock | 2,000 | 261,000 | D |
Explanation of responses
- F1Represents the weighted average sales price of the shares sold ranging from a low of $154.80 to a high of $155.00 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- F2Represents the weighted average sales price of the shares sold ranging from a low of $154.50 to a high of $154.95 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- F3Represents the weighted average sales price of the shares sold ranging from a low of $154.25 to a high of $154.40 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- F4Represents the weighted average sales price of the shares sold ranging from a low of $155.08 to a high of $156.025 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- F5Grant of option to buy 200,000 shares of IDEXX Laboratories, Inc. common stock that became exercisable in five equal annual installments beginning on February 14, 2012 without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.
- F6Not applicable.